Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Coordination and Support Action · Finished

expressPIK expressTEC - From Launch to First MVP

Coordinator
Expresstec - Investigao E Desenvolvimento Em Biotecnologia, Lda, Portugal
Runs
1 July 2023 to 30 June 2024
Status
Finished
EU funding
€75k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101114470

What the project is doing

In the project's own words, from its summary on CORDIS.

Over 600k annual new cases of breast cancer worldwide carry poor prognosis mutations in the gene PIK3CA, but since 2020 a targeted therapeutic option – PIQRAY (alpelisib) – became available, exclusively from Novartis. However, due to the still unsatisfactory response rates, the uptake by doctors and the adherence by patients has been limited. Eligibility is established at present by assessing the PIK3CA status in tumour DNA via companion diagnostic (CDx) tests (from Qiagen and Roche).

However, we found that the level of expression of the PIK3CA mutations, measured in tumour RNA, associates with prognosis and is more accurate to predict the presence of the final mutated protein (the drug target). Hence, we are developing an innovative CDx – expressPIK - that goes beyond the present ones to test the expression of mutations and correctly identify the patients who will benefit from treatment. Our higher accuracy will increase doctors’ confidence in prescribing expressPIK (profitable for expressTEC and investors), and the better response rate (beneficial to patients) will promote patient uptake and treatment adherence (profitable for Novartis).

The total global expressPIK market is over +600 K patients per year. The European Patent pending secures the use of mutation expression levels in clinical diagnosis, for treatment with PIQRAY and other drugs in clinical trials. We are validating the technology and planning to reach the MVP within a year. Women TechEU will support developing our business knowledge and acumen, as well as provide the access to the industry and investors network we are lacking.

We hope to make a change in the survivorship of breast cancer patients, whilst setting an example of female entrepreneurship in a region with high unemployment and low biotech investment.

Topics

Who is involved

OrganisationCityCountryRole
Expresstec - Investigao E Desenvolvimento Em Biotecnologia, LdaFaroPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI